Amoxicillin
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Amoxicillin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Amoxicillin is a beta-lactam antibiotic used in infections such as urinary tract infection, otitis media, pneumonia and pharyngitis. The TxGNN model predicts it may be useful for hyperamylasemia, but no clinical trials and no publications were found for this disease, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Relations recorded in the knowledge graph: urinary tract infection, infectious otitis media, streptococcal infection, bacterial pneumonia, pharyngitis (no approved indication text is available in the local licence records) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available. Amoxicillin is known as a beta-lactam antibiotic that blocks bacterial cell wall synthesis, and its use in bacterial infections is recorded in the knowledge graph.
Based on the data compiled for this report, no plausible mechanistic link to hyperamylasemia could be identified. Amoxicillin has no known action on amylase regulation or on pancreatic or salivary enzyme release. The high score (rank 6778 in the model) is a network-based prediction and should be treated as a hypothesis only, not as a reasoned repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
The local records list 20 valid licences for single-ingredient products (the total is at least 20, so the list may be partial). No approved indication text is recorded for any of them. Up to five are shown below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 83683 | EEshmox DX 250mg/250mg Capsule | Strip of 10 capsules | Not recorded |
| 1386 | Almox DT 125 Tablet | Strip of 10 dispersible tablets | Not recorded |
| 139442 | Monoclav 500 mg/125 mg Tablet | Strip of 10 tablets | Not recorded |
| 198322 | Rotfic Capsule | Strip of 10 capsules | Not recorded |
| 99169 | Grandmox 375mg Tablet | Strip of 10 tablets | Not recorded |
Other available forms include an injection (vial of 20 ml), an oral suspension and a dry syrup.
Safety Considerations
- Drug Interactions: 271 interactions were recorded. Major-level examples include methotrexate and the live cholera vaccine (Vibrio cholerae CVD 103-HgR strain). Moderate-level examples include doxycycline, minocycline, ethinylestradiol, estradiol, mycophenolate mofetil, entecavir and anticoagulants such as dicoumarol and anisindione.
- Relations recorded in the knowledge graph as contraindications (not label text): long QT syndrome, torsades de pointes, liver failure and liver disease, kidney disease, porphyria, cholestasis, myasthenia gravis, Clostridium difficile colitis, ventricular tachycardia, osteoporosis, bone fracture, and infectious mononucleosis. These should be checked against the package insert.
Package insert warnings and contraindications were not available; please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. No clinical trials or publications address hyperamylasemia, and no plausible mechanism links amoxicillin to this condition. The evidence level is therefore L5.
To proceed, the following is needed:
- A credible mechanistic hypothesis for amylase elevation, and mechanism-of-action data for amoxicillin
- Any clinical or preclinical study that directly examines hyperamylasemia
- Package insert warnings and contraindications for the marketed products
- Review of the other predicted indications. Septicemic plague is biologically plausible for an antibacterial, but its evidence is limited to preclinical, in vitro and case-level data, and beta-lactams are not first-line agents for plague.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.